Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Elanco Animal Health Incorporated

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

RAISING FULL YEAR OUTLOOK AND INNOVATION TARGET, IMPROVING YEAR-END NET LEVERAGE RATIO TARGET FIRST QUARTER 2026 FINANCIAL RESULTS: REVENUE OF $1,371 MILLION, AN INCREASE OF 15% YEAR-OVER-YEAR; 10% ORGANIC CONSTANT CURRENCY GROWTH REPORTED NET INCOME OF $57 MILLION, ADJUSTED NET INCOME OF $204 MILLION ADJUSTED EBITDA OF $334 MILLION; ADJUSTED EBITDA MARGIN OF 24.5% REPORTED EPS OF $0.11, ADJUSTED EPS OF $0.40 NET LEVERAGE RATIO OF 3.5X ADJUSTED EBITDA FULL YEAR 2026 GUIDANCE: RAISING INNOVATION REVENUE TARGET TO $1.2 BILLION RAISING REVENUE GUIDANCE TO $5,010 MILLION TO $5,085 MILLION, OR 5% TO 7% ORGANIC CONSTANT CURRENCY GROWTH RAISING ADJUSTED EBITDA TO $975 MILLION TO $1,005 MILLION, A YEAR-OVER-YEAR INCREASE OF 10% AT MIDPOINT RAISING ADJUSTED EPS OF $1.03 TO $1.09, A YEAR-OVER-YEAR INCREASE OF 13% AT MIDPOINT IMPROVING YEAR-END NET LEVERAGE RATIO TARGET TO 3.0X TO 3.2X ADJUSTED EBITDA INDIANAPOLIS, MAY6, 2026 /PRNEWSWIRE/ -- ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2026, PROVIDED GUIDANCE FOR THE SECOND QUARTER OF 2026, AND UPDATED GUIDANCE FOR THE FULL YEAR 2026. "ELANCO'S STRONG FIRST QUARTER RESULTS DEMONSTRATE THE SIGNIFICANT MOMENTUM OF OUR INNOVATION-LED STRATEGY," SAID JEFF SIMMONS, PRESIDENT AND CEO OF ELANCO.

ELANCO ANIMAL HEALTH REPORTS FIRST QUARTER 2026 RESULTS

ACTION PREPARES VETERINARIANS AND LIVESTOCK PRODUCERS WITH PREVENTION AND TREATMENT OPTIONS PRIOR TO FLY BEING DETECTED IN THE U.S. FEDERAL AGENCIES GRANT EMERGENCY AUTHORIZATIONS FOR NEW WORLD SCREWWORM IN LIVESTOCK, REINFORCING ELANCO'S LEADERSHIP IN LIVESTOCK HEALTH INNOVATIONS ACTIONS UNDERSCORE THE COMMITMENT OF THE U.S. FOOD AND DRUG ADMINISTRATION, U.S. ENVIRONMENTAL PROTECTION AGENCY, AND U.S. DEPARTMENT OF AGRICULTURE TO ACT SWIFTLY AGAINST EMERGING ANIMAL HEALTH THREATS EARLY DETECTION AND IMMEDIATE TREATMENT OF OPEN WOUNDS ON LIVESTOCK IS CRITICAL TO PREVENTION OF NEW WORLD SCREWWORM MYIASIS IN INDIVIDUAL ANIMALS AND RAPID SPREAD OF THE PEST AN EFFECTIVE FLY AND TICK CONTROL REGIMEN IS ALSO ESSENTIAL, HELPING TO AVOID SMALL BITES ON ANIMALS THAT CAN BE AN ENTRY POINT FOR THE SCREWWORM INDIANAPOLIS, APRIL 27, 2026 /PRNEWSWIRE/ -- ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) ANNOUNCED IT HAS RECEIVED EMERGENCY USE AUTHORIZATION (EUA) FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR NEGASUNT POWDER (COUMAPHOS, PROPOXUR, SULFANILAMIDE TOPICAL POWDER) AND A SECTION 18 EMERGENCY EXEMPTION FROM THE U.S. ENVIRONMENTAL PROTECTION AGENCY (EPA) IN COOPERATION WITH THE UNITED STATES DEPARTMENT OF AGRICULTURE (USDA) FOR TANIDIL (COUMAPHOS, PROPOXUR) FOR THE PREVENTION AND TREATMENT OF NEW WORLD SCREWWORM INFESTATIONS IN A VARIETY OF LIVESTOCK SPECIES. WITH CONFIRMED CASES OF NEW WORLD SCREWWORM DETECTED AS CLOSE AS 62 MILES SOUTH OF THE U.S.-MEXICO BORDERI,THESE AUTHORIZATIONS ENSURE VETERINARIANS AND LIVESTOCK PRODUCERS HAVE A READY-NOW TREATMENT OPTION FOR VARIOUS LIVESTOCK SPECIES SHOULD THE FLY ENTER THE U.S. NEGASUNT POWDER ANDTANIDIL WILL BE AVAILABLE ONLY THROUGH THE U.S. ANIMAL PLANT HEALTH AND INSPECTION SERVICE (APHIS) AND ITS NATIONAL VETERINARY STOCKPILE.

ELANCO'S NEGASUNT POWDER (COUMAPHOS, PROPOXUR, SULFANILAMIDE TOPICAL POWDER) AND TANIDIL (COUMAPHOS, PROPOXUR) RECEIVE EMERGENCY AUTHORIZATION FOR USE AGAINST NEW WORLD SCREWWORM IN LIVESTOCK

INDIANAPOLIS, APRIL 16, 2026 /PRNEWSWIRE/ -- ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) WILL ANNOUNCE ITS FIRST QUARTER 2026 FINANCIAL RESULTS ON WEDNESDAY, MAY 6, 2026. ELANCO WILL ALSO CONDUCT A CONFERENCE CALL ON THAT DAY WITH THE INVESTMENT COMMUNITY AND MEDIA TO FURTHER DETAIL THE COMPANY'S PERFORMANCE.

ELANCO CONFIRMS DATE AND CONFERENCE CALL FOR FIRST QUARTER 2026 FINANCIAL RESULTS ANNOUNCEMENT

BREAKS THE FLEA LIFECYCLE* WITH PYRIPROXYFEN, AN INSECT GROWTH REGULATOR, PREVENTING FLEAS FROM REINFESTING THE DOG ADJUSTABLE COLLAR FITS COMFORTABLY AND SECURELY ON A DOG OF ANY SIZE STRENGTHENS ELANCO'S 25-YEAR ADVANTAGE BRAND FAMILY AVAILABLE AT PET SPECIALTY, DOLLAR, GROCERY AND MASS RETAILERS, WITH A SUGGESTED RETAIL PRICE BELOW $25** INDIANAPOLIS, APRIL 9, 2026 /PRNEWSWIRE/ -- ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) TODAY ANNOUNCED THE LAUNCH OF ITS ADVANTAGE COLLAR FOR DOGS, A NEW PRODUCT PROVIDING LONG-LASTING PROTECTION AGAINST TWO PARASITES THAT DON'T TAKE A SEASON OFF  FLEAS AND TICKS. DESIGNED FOR DOGS AND PUPPIES 12 WEEKS OF AGE AND OLDER, THIS DOG COLLAR KILLS AND REPELS FLEAS AND TICKS AND REPELS MOSQUITOES* FOR A FULL FOUR MONTHS.

ELANCO LAUNCHES ADVANTAGE COLLAR FOR DOGS WITH FOUR MONTHS OF CONTINUOUS PROTECTION FROM FLEAS, TICKS AND MOSQUITOES*

RAISING 2026 INNOVATION TARGET; FULL YEAR 2026 GUIDANCE OF 4%-6% ORGANIC CONSTANT CURRENCY REVENUE GROWTH, 6%-9% ADJUSTED EBITDA GROWTH IN LINE WITH INVESTOR DAY OUTLOOK FOURTH QUARTER 2025 FINANCIAL RESULTS: REVENUE OF $1,144 MILLION, INCREASED 12% ON A REPORTED BASIS; 9% IN ORGANIC CONSTANT CURRENCY REPORTED NET LOSS OF $276 MILLION, ADJUSTED NET INCOME OF $64 MILLION ADJUSTED EBITDA OF $189 MILLION; ADJUSTED EBITDA MARGIN OF 16.7% REPORTED EPS OF $(0.56), ADJUSTED EPS OF $0.13 FULL YEAR 2025 FINANCIAL RESULTS: EXCEEDED INNOVATION REVENUE TARGET AT $892 MILLION; DELIVERED ALL 'BIG 6' BLOCKBUSTER POTENTIAL PRODUCTS BY THE END OF 2025 WITHBEFRENA APPROVAL IN Q4 2025 REVENUE OF $4,715 MILLION, INCREASED 6% ON A REPORTED BASIS AND 7% IN ORGANIC CONSTANT CURRENCY REPORTED NET LOSS OF $232 MILLION, ADJUSTED NET INCOME OF $473 MILLION ADJUSTED EBITDA OF $901 MILLION; ADJUSTED EBITDA MARGIN OF 19.2% REPORTED EPS OF $(0.47), ADJUSTED EPS OF $0.94 NET LEVERAGE RATIO OF 3.6X ADJUSTED EBITDA FULL YEAR 2026 GUIDANCE: RAISING INNOVATION REVENUE TARGET TO $1.15 BILLION REVENUE OF $4,950 MILLION TO $5,020 MILLION, OR 4% TO 6% ORGANIC CONSTANT CURRENCY GROWTH ADJUSTED EBITDA OF $955 MILLION TO $985 MILLION, AN INCREASE OF 8% AT MIDPOINT ADJUSTED EPS OF $1.00 TO $1.06, AN INCREASE OF 10% AT MIDPOINT YEAR-END NET LEVERAGE RATIO TARGET OF 3.1X TO 3.3X IN LINE WITH THREE-YEAR OUTLOOK INTRODUCED AT DECEMBER INVESTOR DAY, OUTLINING MID-SINGLE DIGIT TOP-LINE ORGANIC CONSTANT CURRENCY GROWTH, HIGH-SINGLE DIGIT ADJUSTED EBITDA GROWTH, AND LOW DOUBLE-DIGIT ADJUSTED EPS GROWTH INDIANAPOLIS, FEB. 24, 2026 /PRNEWSWIRE/ -- ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) TODAY REPORTED ITS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2025 AND PROVIDED INITIAL GUIDANCE FOR BOTH THE FIRST QUARTER AND FULL YEAR 2026. "ELANCO DELIVERED SIGNIFICANT PROGRESS ACROSS OUR STRATEGIC PRIORITIES OF GROWTH, INNOVATION, AND CASH IN 2025," SAID JEFF SIMMONS, PRESIDENT AND CEO OF ELANCO.

ELANCO ANIMAL HEALTH REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS

INDIANAPOLIS, IND., FEB. 19, 2026 /PRNEWSWIRE/ -- ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN UPCOMING INVESTOR CONFERENCES.

ELANCO TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

INDIANAPOLIS, FEB. 13, 2026 /PRNEWSWIRE/ -- ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) TODAY ANNOUNCED UPDATES TO ITS BOARD OF DIRECTORS. R. DAVID HOOVER AND DEBORAH KOCHEVAR WILL NOT STAND FOR RE-ELECTION AT THE CONCLUSION OF THEIR TERMS AT THE 2026 ANNUAL MEETING OF SHAREHOLDERS IN MAY.

ELANCO ANNOUNCES UPDATES TO BOARD OF DIRECTORS

INDIANAPOLIS, JAN. 22, 2026 /PRNEWSWIRE/ -- ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) WILL ANNOUNCE ITS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS ON TUESDAY, FEBRUARY 24, 2026. ELANCO WILL ALSO CONDUCT A CONFERENCE CALL ON THAT DAY WITH THE INVESTMENT COMMUNITY AND MEDIA TO FURTHER DETAIL THE COMPANY'S PERFORMANCE.

ELANCO CONFIRMS DATE AND CONFERENCE CALL FOR FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS ANNOUNCEMENT

INDIANAPOLIS, JAN. 6, 2026 /PRNEWSWIRE/ --ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) WILL PARTICIPATE IN THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE ON TUESDAY, JANUARY 13, 2026.

ELANCO TO PARTICIPATE IN THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

ELANCO'S SECOND DERMATOLOGY PRODUCT APPROVAL IN LESS THAN 18 MONTHS IN THE ESTIMATED $1.3 BILLION U.S. CANINE DERMATOLOGY MARKET BEFRENA HAS BEEN SHOWN TO BE EFFECTIVE FOR TREATMENT OF DOGS OF ANY AGE AGAINST CANINE ATOPIC DERMATITIS AND ALLERGIC DERMATITIS FOR 6 TO 8 WEEKS OF TREATMENT, AS NEEDED USDA APPROVAL OFBEFRENA REINFORCES ELANCO'S COMMITMENT TO GOING BEYOND TO DELIVER DIFFERENTIATED, HIGH-QUALITY PRODUCTS IN EVERY KEY THERAPEUTIC AREA, BOLSTERING ITS LEADERSHIP IN CANINE DERMATOLOGY AND MONOCLONAL ANTIBODIES (MABS) CANINE ALLERGIC ANDATOPIC DERMATITIS IS A WIDESPREAD CONCERN AMONGST VETERINARIANS, WITH DATA REVEALING THAT NEARLY 98% OF VETS SAY THEY ROUTINELY TREAT DOGS FOR ATOPIC DERMATITIS AND THAT ITCHY DOGS MAKE UP NEARLY 20% OF THEIR PATIENT POPULATIONI INDIANAPOLIS, IND., DEC. 31, 2025 /PRNEWSWIRE/ -- ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) TODAY ANNOUNCED ITS LATEST ENTRY INTO THE RAPIDLY GROWING CANINE DERMATOLOGY SPACE WITH THE U.S. DEPARTMENT OF AGRICULTURE (USDA) APPROVAL OF BEFRENA (TIRNOVETMAB), A NEW ANTI-IL31 MONOCLONAL ANTIBODY (MAB) INJECTION TARGETING CANINE ALLERGIC AND ATOPIC DERMATITIS.

Elanco Animal Health Incorporated

ELAN

Price

Financial Reports

No items found.

Press Releases

Elanco Animal Health Incorporated

ELAN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ELAN